HIV patients with cancer must travel farther than others to access clinical trials
A new study published in JAMA Network Open reveals that HIV-positive cancer patients face significantly longer travel times to access CAR-T clinical trials compared to other patients. Researchers suggest that geographic barriers are creating inequitable access to life-saving cancer treatments for this demographic.
Why it matters
It identifies a critical healthcare disparity that prevents vulnerable populations from accessing advanced medical therapies.
by Christine Grashorn, University of Notre Dame
edited by Gaby Clark , reviewed by Alexander Pol
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source From "Geospatial Access to CAR-T Clinical Trials for Non-Hodgkin Lymphoma for Persons With HIV," Maps of Prevalence of Trials by HIV Inclusion and/or ExclusionA and B, Color density in the key for each range is based on deciles of trials per 100 000 persons with HIV (PWH) calculated for trials that included PWH. Credit: © 2026 Maillie L et al. JAMA Network Open. CC-BY License For people living with HIV, the road to a promising cancer treatment can be longer than it should be, literally.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in